Contact hours available until 6/30/2017.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Nephrology Nursing Journal Editorial Board Statements of Disclosure
In accordance with ANCC governing rules Nephrology Nursing Journal Editorial Board statements of disclosure are published with each CNE offering. The statements of disclosure for this offering are published below.

Paula Dutka MSN, RN, CNN, disclosed that she is a coordinator of Clinical Trials for the following sponsors: Amgen, Rockwell Medical, Keryx Biopharmaceuticals, Akebia Therapeutics, and Dynavax Technologies.

Carol M. Headley DNSc, ACNP-BC, RN, CNN, disclosed that she is a Consultant and/or member of the Corporate Speaker’s Bureau for Sanofi Renal, and a member of the Advisory Board for Amgen.

Tamara M. Kear, PhD, RN, CNS, CNN, disclosed that she is a Fresenius employee, freelance editor for Lippincott Williams & Wilkins and Elsevier publishing companies.

All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.

This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Hazel A. Dennison, DNP, RN, APNc, CPHQ, CNE, ANNA Education Director.

There are no other disclosures to declare.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Goal
To provide an overview of a pilot project designed to improve knowledge and self-management among Medicaid beneficiaries with chronic kidney disease 9CKD) Stages 3b and 4.

Objectives:

Discuss the use of a population-based approach to identify individuals with CKD Stages 3b and 4.
Describe the results of a nurse-led education intervention pilot study to improve knowledge and self-management individuals with CKD Stages 3b and 4.

Ronald J. Falk MD

Appearances